Mox CV

Quick links to important sections

Mox CV

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mox CV

Mox CV is a prescription-only brand-name medication that functions as a combination antibiotic. It is used to treat infections caused by bacteria that have developed resistance to standard penicillin-class antibiotics alone. This particular formulation is clinically recognized for its effectiveness against a broad range of bacterial pathogens.

Quick Facts

Property Description
Active Ingredients Amoxicillin and Clavulanate Potassium
Form Oral (tablets, liquid suspension)
Pharmacological Class Penicillin Antibiotic + Beta-Lactamase Inhibitor
Primary Use Treating specific bacterial infections (e.g., ear, sinus, lung)
Prescription Status Prescription Only (Rx)

Mox CV combines two active components. Amoxicillin is an antibiotic from the penicillin family whose role is to destroy bacteria by interfering with their cell wall formation. However, certain bacteria produce an enzyme called beta-lactamase, which inactivates amoxicillin.

The second component, clavulanate potassium, is a beta-lactamase inhibitor. It acts as a protective shield for the amoxicillin by deactivating the enzyme, thereby restoring the antibiotic's ability to kill the bacteria. The combination is approved for treating various bacterial infections, including those affecting the ear, sinuses, lower respiratory tract, and skin. It is crucial to remember that this prescription medicine specifically targets bacteria and is not effective against viruses, such as the common cold or flu.

What side effects are possible with Mox CV?

Possible Side Effects and Safety Information

Mox CV, a combination of amoxicillin and clavulanate potassium, carries a distinct safety profile centered on common gastrointestinal disturbances and critical warnings regarding hypersensitivity and organ system issues.

Adverse Reactions Overview

Category Common Reactions (Frequency: 1% to 10%) Serious/Clinically Significant Reactions
Gastrointestinal Diarrhea/loose stools, nausea, vomiting Clostridioides difficile-associated diarrhea (CDAD), severe persistent diarrhea, abdominal pain
Immune/Skin Skin rash, itching, urticaria (hives) Serious hypersensitivity reactions (e.g., anaphylaxis, Stevens-Johnson Syndrome [SJS], Toxic Epidermal Necrolysis [TEN], DRESS)
Hepatobiliary Cholestatic jaundice, hepatitis, and hepatic dysfunction
Other Vaginal yeast infection (vaginitis), fungal infections Seizures/convulsions (especially in renal impairment or overdose)

Safety Restrictions and Monitoring

Contraindications: The use of Mox CV is strictly contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis or SJS) to the drug or to any other beta-lactam antibiotics (like penicillins or cephalosporins). It is also contraindicated in individuals who have experienced cholestatic jaundice or hepatic dysfunction previously associated with its use.

Population Considerations: Caution is advised when prescribing to patients with pre-existing hepatic impairment, where liver function tests should be monitored. Patients with renal impairment may require dosage adjustments due to the drug’s primary renal elimination, and the extended-release formulation is not recommended in severe renal impairment. A rash may occur in patients with mononucleosis; therefore, use in this population is generally avoided.

Drug Interactions: Mox CV may reduce the efficacy of oral contraceptives and is known to increase the risk of rash when co-administered with allopurinol.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Mox CV (Amoxicillin/Clavulanate Potassium) requires immediate medical attention. Regulatory guidance mandates that individuals must seek emergency medical help or contact a poison control center right away if an overdose is suspected. This immediate action is necessary due to the potential for severe, documented complications.

Officially reported overdose presentations primarily involve the gastrointestinal and renal systems. Manifestations include nausea, vomiting, stomach pain, and diarrhea. More serious outcomes relate to Central Nervous System (CNS) effects, such as hyperactivity and the potential for seizures (convulsions), and the specific risk of amoxicillin-related crystalluria (crystal formation in the urine). Crystalluria is a severe renal complication that can result in greatly decreased urine output.

Management involves the discontinuation of the medication, followed by supportive and symptomatic treatment. No specific antidote is known. Official information notes that hemodialysis is an effective, documented procedure for removing both drug components from the circulation. A key consideration is the increased risk of toxicity for patients with impaired renal function, who are more susceptible to the accumulation of the drug and associated effects like convulsions.

Therapeutic Uses of Mox CV

Mox CV is commonly used when a bacterial infection is suspected to involve resistant pathogens—in situations where resistance is a concern. Its primary therapeutic benefit is to provide targeted support across several core body systems, assisting with the management of acute symptoms and contributing to easing the overall symptom load. The combination is applied in the management of infections of the lower respiratory tract, acute otitis media, sinusitis, skin and soft tissue, and the urinary tract.

This antibiotic combination is relevant in clinical settings marked by heightened patient distress, such as acute exacerbations of chronic lung conditions or when an infection has not responded adequately to initial therapy. The therapy is used to address symptom clusters that include fever, localized pain, inflammation, and respiratory distress.

“The core benefit of this combination is providing support that helps ease the overall symptom burden during challenging acute episodes.”

Focused Support for Specific Symptom Domains

Mox CV is used for managing conditions that present with disruptive symptom manifestations across several key domains. In respiratory infections, it helps address groups of symptoms that may appear suddenly, like severe cough and chest discomfort. For skin infections, it supports the handling of localized inflammation, redness, and swelling. In these conditions, Mox CV assists with maintaining functional stability and general well-being during difficult episodes.


Quick Fact: Focus on Acute Symptom Intensity

Condition Category Symptom Management Focus
Respiratory & Ear Easing fever, pain, and congestion
Skin & Soft Tissue Addressing localized inflammation and pain
Systemic & Urinary Supporting relief from acute pain and discomfort

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Mox CV (amoxicillin and clavulanate potassium) eligibility is strictly defined by regulatory documents, emphasizing absolute exclusions and conditions that require restricted use.

Who Cannot Use Mox CV (Contraindications)

Classification Population Restriction
Absolute Exclusion Individuals with a history of a serious hypersensitivity reaction to any beta-lactam antibiotic (penicillins, cephalosporins) or to Mox CV itself.
Organ History Patients with a prior history of cholestatic jaundice or hepatic dysfunction specifically associated with previous use of this combination

Age, Organ Function, and Conditional Use

Age-Group Eligibility: The medicine is generally permitted for adults and pediatric patients aged 12 weeks/3 months and older. Specific high-dose tablet formulations are not recommended for children under 40 kg.

Organ Restrictions: Use requires caution in patients with evidence of hepatic impairment, and monitoring is necessary. Patients with severe renal impairment (creatinine clearance < 30 mL/min) require mandatory dose adjustment for standard formulations, and the extended-release tablet form is contraindicated.

Conditional Restrictions: Mox CV should be avoided in individuals with infectious mononucleosis. During pregnancy and lactation, use is generally allowed only if clearly needed and requires caution.

What should I know about interactions with other medicines?

The official regulatory documentation for Mox CV (Amoxicillin and Clavulanate Potassium) details several clinically significant interactions with other medicinal products, categorized by their effects on drug exposure and overall outcomes.

Interactions Affecting Drug Exposure

The co-administration of Probenecid is not recommended, as it delays the renal excretion of the amoxicillin component, resulting in increased and prolonged blood levels of amoxicillin. Amoxicillin can also elevate serum concentrations of Methotrexate by reducing its clearance. This pharmacokinetic interaction is particularly relevant for patients with reduced renal function, who face a heightened risk of methotrexate toxicity.

Pharmacodynamic and Outcome Interactions

Concomitant use with Oral Anticoagulants (such as Warfarin) may lead to the abnormal prolongation of prothrombin time and an increase in the International Normalized Ratio (INR). Monitoring of coagulation parameters is required for this combination, especially in the elderly or those with underlying liver or kidney issues. Co-administration with Allopurinol is documented to increase the risk of developing a skin rash. Additionally, the efficacy of Oral Contraceptives containing estrogen and progesterone may be reduced.

Drug-Food Interaction

The official label states that the absorption of the clavulanate potassium component is enhanced when Mox CV is administered at the start of a meal.

Mechanism of Action

Irreversible Inactivation of Bacterial Cell Wall Synthesis

The amoxicillin component works by permanently binding to bacterial Penicillin-Binding Proteins (PBPs), the enzymes required for constructing the rigid bacterial cell wall. This specific action halts the final step of wall synthesis, which directly leads to the structural collapse and osmotic lysis (rupture) of the bacteria, resulting in bacterial lysis and a bactericidal consequence.

Targeted Neutralization of Resistance Enzymes

The clavulanate potassium component functions as a protective agent that targets and irreversibly destroys bacterial beta-lactamase enzymes. These enzymes are the primary defense mechanism used by resistant bacteria to inactivate amoxicillin. By eliminating this enzyme, clavulanate restores the full functional activity of the amoxicillin, ensuring the cell wall inhibition mechanism is functionally available to proceed against resistance-producing strains.

Mechanistic Constraints and Bypassed Pathways

The combined mechanism can be constrained when bacteria develop alternative resistance methods, such as modifying the structure of the PBPs to reduce amoxicillin binding affinity, or when the bacteria produce advanced resistance enzymes, like certain Extended Spectrum beta-Lactamases (ESBLs), which the clavulanate component cannot effectively neutralize. This constrains the bactericidal cascade where the resistance mechanism is bypassed.

Dosage and Administration Information

How to Use Mox CV: Administration Guidelines

Mox CV (Amoxicillin/Clavulanate Potassium) is administered primarily via the oral route (tablets or suspension) for outpatient use, with intravenous (IV) forms available for hospital-based systemic treatment. Standardized instructions for dosage and administration are used to maintain the medicine's correct usage profile.


Dosing and Frequency (Adults 40 kg)

The medicine is generally taken either two or three times daily, depending on the prescribed tablet strength, which is determined by the specific treatment needs:

Strength (Amoxicillin/Clavulanate) Frequency Regimen Type Duration Pattern
875 mg/125 mg Every 12 hours (Twice Daily) Higher dose Typically 7–14 days
500 mg/125 mg Every 8 hours (Three Times Daily) Standard dose Typically 7–14 days

Key Administration Conditions

  1. Timing with Meals: All oral forms must be taken at the start of a meal. This condition minimizes potential gastrointestinal issues and enhances the absorption of the clavulanate component.
  2. Renal Adjustment: Dose modification is required for adults with severe renal impairment (creatinine clearance < 30 mL/min). The 875 mg/125 mg tablet strength is restricted in this population, with lower doses given at reduced frequency (e.g., every 12 or 24 hours). Patients on hemodialysis receive an additional dose during or at the end of the dialysis session.
  3. Treatment Duration: The course of treatment typically lasts 7 to 14 days. Therapy should not be extended beyond 14 days without careful review of the case.
  4. Suspension Preparation: For liquid forms, the powder must be reconstituted by adding water in two portions and shaking vigorously. The bottle must be shaken well before each dose is measured for administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Mox CV

This overview summarizes the type of research available for Mox CV (Amoxicillin/Clavulanate) across its approved uses, detailing what outcomes were measured and where the current research landscape may have limitations.


Evidence Base for Acute Respiratory and Ear Infections

This section summarizes the available short-term research, including Randomized Controlled Trials (RCTs) and comparative studies, conducted to explore the use of Mox CV in studies related to conditions affecting the lower respiratory tract, the middle ear, and the sinuses.

Research Focus on Lower Respiratory Tract Infections (LRTIs)

Research has explored the use of Mox CV in patient groups, including adults and older adults, with lower respiratory tract conditions. Studies conducted during periods of increased symptom activity examined endpoints related to the resolution of acute signs, such as cough and fever, and monitored bacteriological status of targeted pathogens, especially those that produce beta-lactamase enzymes. Findings describe patterns observed over defined observation periods, usually lasting between 7 and 15 days. Long-term clinical and functional outcomes beyond this period are not well characterized.

Research Focus on Acute Otitis Media (AOM) and Sinusitis

Studies have been conducted for acute otitis media and acute bacterial sinusitis, using short-term RCTs and dose-finding trials. These studies primarily measure endpoints related to the final status of signs in the ear or sinuses, and microbiological status in the observed populations. The research has explored the evaluation of Mox CV use in pediatric populations, including infants and young children. Evidence for sinusitis remains heterogeneous due to differing criteria for defining endpoints. The durability of the microbiological outcome beyond the short-term follow-up window is not always extensively documented.


Evidence in Specific Patient Populations and Research Uncertainty

Research has explored the evaluation of Mox CV use in several distinct groups, including children and older adults. Studies have also included patient cohorts with underlying chronic conditions, such as chronic lung disease, examining responses during periods of heightened symptoms. Data for certain subgroups, however, remain insufficient.

Overall, the available evidence primarily consists of short-term trials. Research provides insight into short-term changes, but long-term effects are not well characterized. Comparative evidence with some alternative antibiotic treatments is lacking in direct head-to-head studies for all indications, and for some infections, the sample sizes were modest, contributing to uncertainty in findings for specific subgroups.

Key Studies & References

  1. Label: AMOXICILLIN AND CLAVULANATE POTASSIUM tablet - DailyMed - NIH
  2. Evaluation of Oral Amoxicillin/Clavulanate for Urinary Tract Infections Caused by Ceftriaxone Non-Susceptible Enterobacterales

Frequently Asked Questions (FAQ)

Common questions about Mox CV (FAQ)

Q: What happens if I forget to take a dose of Mox CV?

Regulatory patient information states it can be taken as soon as you remember if a dose is missed. However, if it is nearly time for your next scheduled dose, the missed dose should be skipped, and the regular schedule should be continued. Regulatory patient information states that double doses are not recommended to compensate for a missed dose.

Q: How long after starting Mox CV should I expect to feel better?

Official patient instructions state that improvements are often noticed during the first few days of treatment with the medicine. The full therapeutic effect is intended to be achieved by completing the entire prescribed course.

Q: Is it safe to take Mox CV with painkillers like ibuprofen?

Regulatory documents state that this medicine has documented interactions with specific products, such as certain anticoagulants and gout medications. The official drug label does not list a specific interaction warning for non-prescription ibuprofen.

Q: Does alcohol interact with Mox CV?

Official patient information advises avoiding alcohol during the course of treatment with this medicine and for several days after completing it.

Q: Can Mox CV affect birth control pills?

Yes, official regulatory documentation describes that, in common with other broad-spectrum antibiotics, this medicine may potentially reduce the effectiveness of oral contraceptives that contain estrogen and progesterone.

Q: Is there any risk associated with taking Mox CV if I have kidney problems?

The medicine is primarily removed from the body by the kidneys, and elimination can be delayed in patients with kidney problems. Because of this, official guidelines specify that dosage adjustments may be necessary for adults with severe renal impairment, and certain formulations may be restricted in this population.

Q: Can children take Mox CV, and is the dosage different?

The medicine is permitted for use in pediatric patients starting from 12 weeks of age. Regulatory guidelines provide modified dosing instructions for infants younger than 12 weeks and also specify different doses based on various age and weight groups.

Q: Can I crush or split the Mox CV tablet?

Most standard tablets of this medicine are intended to be swallowed whole. Regulatory guidance often advises against crushing or splitting standard tablets, and official regulatory guidance specifies that extended-release formulations should not be crushed or chewed, as this may alter how the medicine is released into the body.

Q: How quickly does Mox CV usually start to work?

While the clinical effect (feeling better) is usually noticed after a few days, the medicine begins its therapeutic action immediately after it is absorbed into the bloodstream. It works by interfering with the structural formation of bacterial cells.

Q: What are the most common mild side effects reported for Mox CV?

The most commonly reported mild reactions in official safety data are gastrointestinal issues. These typically include diarrhea, nausea, and vomiting, and sometimes the appearance of a skin rash.

Q: Are there any serious side effects of Mox CV that I should be aware of?

Regulatory documents list serious, but rare, reactions including severe allergic reactions (such as anaphylaxis and severe skin reactions), severe persistent diarrhea (CDAD), and potential liver problems (hepatitis or jaundice) that may be clinically significant.

Q: Can Mox CV cause stomach upset or diarrhea?

Yes. Official safety data lists gastrointestinal issues, including diarrhea and nausea/vomiting, as common adverse reactions (occurring in 1% to 10% of patients in studies). Taking the medicine at the start of a meal is a key administration condition intended to minimize these potential issues.

Q: Is it common for Mox CV to cause a rash?

Yes, the occurrence of a general skin rash is listed as a common adverse reaction in official safety data. If a rash is severe, such as involving blisters or peeling, official information describes this as a sign that may indicate a serious allergic reaction.

Q: Does Mox CV make me sleepy or affect my ability to drive?

Regulatory guidance indicates the medicine generally does not affect the ability to drive or operate machinery. However, effects like dizziness or tiredness can occur in some individuals, and it is noted that caution should be exercised if these effects occur.

Q: If I finish the prescribed course of Mox CV early, what happens?

Official patient information stresses the importance of completing the full prescribed course of treatment. Stopping the medicine too soon risks the infection not being fully treated and may contribute to the bacteria developing resistance to the medicine.

Q: How long does Mox CV stay in your system after you stop taking it?

The active components of the medicine are rapidly eliminated from the body, primarily through the kidneys. In individuals with normal kidney function, the components typically have a short half-life and are largely cleared from the system within approximately five hours of the last dose.

Q: Are there different strengths or formulations of Mox CV available?

Yes, regulatory drug guides list various strengths and formulations of the medicine. These include immediate-release tablets, chewable tablets, and oral suspensions, which are prescribed based on the type of infection and the patient’s clinical status.

Q: What is the difference between Mox CV and amoxicillin alone?

The key difference is the addition of the clavulanate component, which is a beta-lactamase inhibitor. This component protects the amoxicillin from being destroyed by bacterial enzymes, thereby extending the medicine's range of activity against bacteria that have developed resistance.

Q: What should I do if my symptoms don't improve after a few days on Mox CV?

Official patient instructions state that if symptoms do not begin to improve or if they worsen after a few days of treatment with the medicine, official patient instructions indicate that contacting a healthcare professional for review is appropriate.

Q: Is Mox CV the same as Augmentin or other branded versions?

Mox CV (amoxicillin/clavulanate potassium) is the common name for this combination medicine. Augmentin is one of the well-known brand names under which this combination is sold, along with various generic versions.

Q: Can Mox CV cause dizziness or headaches?

While not listed as one of the most common adverse effects, official patient information mentions that effects such as dizziness or tiredness may occur in some individuals who take this medicine.

Q: Does Mox CV interfere with blood clotting or INR tests?

Official warnings note that when this medicine is used alongside oral anticoagulants (like Warfarin), it may lead to an abnormal prolongation of prothrombin time and an increase in the International Normalized Ratio (INR). Regulatory warnings indicate that monitoring of blood coagulation parameters may be appropriate when these medicines are used together.

Q: Does Mox CV interact with herbal supplements?

Official guidance notes that interactions with herbal remedies and supplements are typically not fully tested in the same way as prescription medicines. Regulatory guidance suggests consulting a healthcare professional if they are being used alongside this medicine.

Q: Is Mox CV commonly used for sinus infections?

Yes, the medicine is approved by regulatory bodies for treating acute bacterial sinusitis. This is a recognized indication, and official product information provides a specified dosage regimen for this infection.

Q: How should Mox CV be stored?

Tablets and the dry powder for suspension must be stored at controlled room temperature and protected from moisture. The reconstituted liquid suspension must be stored in a refrigerator and should be discarded after 10 days, as specified in regulatory guidance.

Q: Does taking Mox CV affect my gut bacteria?

The medicine, like other antibiotics, may affect the balance of bacteria in the gut. This disruption is what can lead to common side effects such as diarrhea and, in rare cases, more severe persistent diarrhea.

Q: Can I take Mox CV if I am allergic to penicillin?

Regulatory documents strictly prohibit the use of this medicine in individuals with a history of a serious hypersensitivity reaction (allergic reaction) to any beta-lactam antibiotic, which includes penicillins.

Q: What are the signs of a severe allergic reaction to Mox CV?

Signs of a severe allergic reaction as described in official patient information include difficulty breathing, swelling of the face, lips, or tongue, and severe skin reactions like blistering or a widespread rash. These signs are described as requiring immediate medical attention.

Q: Is Mox CV an old or new drug?

The combination drug was approved for medical use in the early 1980s. It has been available globally as a generic medication for several decades.

Q: Is Mox CV considered a narrow-spectrum or broad-spectrum medicine?

The medicine is generally described in regulatory and clinical texts as a broad-spectrum combination antibiotic due to the clavulanate component protecting the amoxicillin from various bacterial defense mechanisms.

Q: Is the research evidence for Mox CV considered strong?

Regulatory summaries of the research evidence note that studies primarily consist of short-term trials. It is also noted that long-term effects are not always fully characterized, and comparative evidence with some alternative treatments is lacking in direct head-to-head studies for all approved uses.

How should Mox CV be stored and disposed of?

Storage and Disposal of Mox CV (Amoxicillin and Clavulanate Potassium)

The official requirements for storing Mox CV differ based on the form. Tablets and the dry powder for suspension must be stored at controlled room temperature, 20 C to 25 C (68 F to 77 F) [1.3]. All dry forms require protection from moisture and light and should be kept in the original, tightly closed container [1.3], [3.6].

The reconstituted liquid suspension must be stored in a refrigerator (2 C to 8 C) and must not be frozen [2.2], [2.3]. This liquid is stable for 10 days and must be discarded thereafter [2.2]. All forms must be stored out of the reach of children [1.3].

Disposal of unused or expired medicine should follow official regulatory guidance, preferably through a drug take-back program [3.1]. If using household trash, the medicine must be rendered undesirable and placed in a sealed container, avoiding environmental release [3.1], [3.5].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Mox CV found in:

A-Z Index: